Comparative Pharmacology
Head-to-head clinical analysis: HEPTALAC versus LAXILOSE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEPTALAC versus LAXILOSE.
HEPTALAC vs LAXILOSE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ammonia scavenger; lactulose is metabolized by colonic bacteria to organic acids, acidifying the colon, which converts NH3 to NH4+ and promotes ammonia excretion. Lactulose also reduces colonic transit time and bacterial production of ammonia.
Laxilose (lactulose) is a synthetic disaccharide that is not absorbed in the small intestine. In the colon, it is metabolized by bacteria to short-chain fatty acids (e.g., lactic, acetic, formic acids), which osmotically draw water into the bowel lumen, stimulating peristalsis and softening stools. Additionally, in hepatic encephalopathy, colonic acidification traps ammonia (NH3) as ammonium (NH4+), reducing systemic ammonia absorption.
Oral: 3.33 g (30 mL) 3 times daily. Rectal: 200 mL of 30% solution as retention enema, 3 times daily. Intravenous: 30 g as a single dose via intra-abdominal instillation.
10-20 g (15-30 mL) orally once daily; may increase to 40 g (60 mL) daily in divided doses.
None Documented
None Documented
Terminal elimination half-life is 6-12 hours in patients with normal hepatic function; prolonged in hepatic encephalopathy due to altered clearance (up to 24 hours).
Terminal elimination half-life is 2.5-4 hours in patients with normal renal function; prolonged to up to 20 hours in severe renal impairment.
Primarily renal (approximately 70-80%) as unchanged drug; minor biliary/fecal elimination (20-30%).
Primarily renal excretion, with approximately 40% of the dose recovered as unchanged drug in urine; biliary/fecal excretion accounts for the remainder, including metabolites.
Category C
Category C
Laxative
Laxative